The Competition and Consumer Commission of Singapore (“CCCS”) has cleared the proposed acquisition by Fresenius Medical Care Singapore Pte. Ltd. (“FMC SG”) of 100% of the issued share capital in RenalTeam Pte. Ltd. (“RT”) (collectively, the “Parties”) (the “Proposed Transaction”).

Following its assessment, CCCS has concluded that the Proposed Transaction, if carried into effect, will not infringe the section 54 prohibition of the Competition Act (Cap. 50B) (the “Act”).

Read the full media release here.